Flexion Therapeutics

Flexion Therapeutics is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on developing and commercializing a sustained release version of triamcinolone acetonide that is intended to be injected into the joint to treat osteoarthritis.[1][2]

Flexion Therapeutics, Inc.
Public
Traded asNASDAQ: FLXN
Russell 2000 Component
IndustryPharmaceuticals
Founded2007
HeadquartersBurlington, MA
WebsiteFlexion Therapeutics

It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.[3]

In November 2016 the FDA accepted Flexion's New Drug Application for FX006, an extended-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".[4][5] In March 2017 FiercePharma reported that Flexion was in discussions with Sanofi about a possible acquisition, valued at the time at around $1 billion.[4] In October 2017 Zilretta was approved by the FDA as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain. [6]

Flexion had been developing FX007, a selective small-molecule TrkA inhibitor that it had licensed from AstraZeneca, for osteoarthritis.[7] As of March 2017 Flexion had terminated development.[8] Flexion had also terminated development of FX005, a P38 mitogen-activated protein kinase inhibitor, by that time.[9] In December 2017, Flexion acquired a gene therapy product candidate for the treatment of osteoarthritis, known as FX201.[10] In September 2019, Flexion announced the acquisition of a locally administered NaV1.7 inhibitor formulated for extended-release in a thermosensitive hydrogel, known as FX301.[11]

References
  1. Gormley, Brian. (28 November 2011). "Flexion Changes Endgame, Advances Osteoarthritis Drugs." Dow Jones VentureWire.
  2. Young, Robin (March 8, 2012). "Could This Be Orthopedics' Future?". Orthopedics This Week. Archived from the original on May 14, 2012.
  3. Weisman, Robert (December 12, 2016). "2 biotechs look to market knee pain treatments - The Boston Globe". Boston Globe.
  4. Staton, Tracy (March 23, 2017). "Sanofi on verge of $1B-plus deal for arthritis-focused biotech Flexion: source". FiercePharma.
  5. "Triamcinolone acetonide sustained-release". AdisInsight. Retrieved 17 July 2017.
  6. Inc, Flexion Therapeutics (2017-10-06). "Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain". GlobeNewswire News Room. Retrieved 2020-01-24.
  7. Kavanaugh, Taylor E.; Werfel, Thomas A.; Cho, Hongsik; Hasty, Karen A.; Duvall, Craig L. (2015). "Particle-based technologies for osteoarthritis detection and therapy". Drug Delivery and Translational Research. 6: 132–47. doi:10.1007/s13346-015-0234-2. ISSN 2190-393X. PMC 4654703. PMID 25990835.
  8. "FX 007". AdisInsight. Retrieved 17 July 2017.
  9. "FX 005". AdisInsight. Retrieved 17 July 2017.
  10. "Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee". www.bloomberg.com. Retrieved 2020-01-24.
  11. "Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain". BioSpace. Retrieved 2020-01-24.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.